Spirometry, rapid FEV1 decline, and lung cancer among asbestos exposed heavy smokers

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 4, Issue 4, 2007, Pages 339-346

  Chien, Jason W ^a   Au, David H ^b   Barnett, Matt J ^a   Goodman, Gary E ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Puget Sound Veterans Administration Health Care System   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

Author keywords

COPD; Lung cancer; Risk factors

Indexed keywords

ASBESTOS; BETA CAROTENE; RETINOL; VITAMIN;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CANCER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SPIROMETRY; THORAX RADIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ENVIRONMENTAL EXPOSURE; INCIDENCE; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING;

AGED; ASBESTOS; BETA CAROTENE; DOUBLE-BLIND METHOD; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RISK FACTORS; SMOKING; SPIROMETRY; VITAMIN A; VITAMINS;

EID: 36248944148     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550701601340     Document Type: Article

References (30)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary (Review). Am J Respir Crit Care Med 2001; 163:1256-1276.
2. Burrows B. Predictors of loss of lung function and mortality in obstructive lung disease. Eur Respir Rev 1991; 1:340-345.
3. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149:13-20.
4. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, Calia N, Petruzzelli S, Corbetta L, Cavallesco G, Forini E, Saetta M, Ciaccia A, Fabbri LM. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004; 59:679-681.
5. Eberly LE, Ockene J, Sherwin R, Yang L, Kuller L, Multiple Risk Factor Intervention Trial Research Group. Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters. Int J Epidemiol 2003; 32:592-599.
6. Cullen MR, Barnett MJ, Balmes JR, Cartmel B, Redlich CA, Brodkin CA, Barnhart S, Rosenstock L, Goodman GE, Hammar SP, Thornquist MD, Omenn GS. Predictors of lung cancer among asbestos-exposed men in the beta-carotene and retinol efficacy trial. Am J Epidemiol 2005; 161:260-270.
7. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
8. Goodman GE, Omenn GS, Thornquist MD, Lund B, Metch B, Gylys-Colwell I. The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers. Cancer Epidemiol Biomarkers Prev 1993; 2:389-396.
9. Barnhart S, Keogh J, Cullen MR, Brodkin C, Liu D, Goodman G, Valanis B, Glass A, Thornquist M, Rosenstock L, Omenn G, Balmes J. The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts. Am J Ind Med 1997; 32:573-581.
10. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664.
11. Fletcher CM, Peto R, Tinker C, Speizer FE. An Eight-Year Study of Early Chronic Obstructive Lung Disease in Working Men in London, In: The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press, 1976.
12. Sorlie PD, Kannel WB, O'Connor G. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis 1989; 140:379-384.
13. Enright RL, Connett JE, Bailey WC. The FEV1/FEV6 predicts lung function decline in adult smokers. Respir Med 2002; 96:444-449.
14. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WAJ, Enright PL, Kanner RE, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J Am Med Assoc 1994; 272:1497-1505.
15. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60:570-575.
16. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koeter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55:12-18.
17. Maestrelli P, Saetta M, Di Stefano A, Calcagni PG, Turato G, Ruggieri MP, Roggeri A, Mapp CE, Fabbri LM. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152:1926-1931.
18. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989; 140:1527-1537.
19. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645-2653.
20. de Visser KE, Coussens LM. The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol Immunother 2005; 54:1143-1152.
21. Kocazeybek B. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J Med Microbiol 2003;52:721-726.
22. Anttila T, Koskela P, Leinonen M, Laukkanen P, Hakulinen T, Lehtinen M, Pukkala E, Paavonen J, Saikku P. Chlamydia pneumoniae infection and the risk of female early-onset lung cancer. Int J Cancer 2003; 107:681-682.
23. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE, Vaughan TL. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:1624-1630.
24. Celli BR, Halbert RJ, Nordyke RJ, Schau B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005; 118:1364-1372.
25. Wilk JB, Djousse L, Arnett DK, Rich SS, Province MA, Hunt SC, Crapo RO, Higgins M, Myers RH. Evidence for major genes influencing pulmonary function in the NHLBI family heart study. Genet Epidemiol 2000; 19:81-94.
26. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170:691-715.
27. Ohar J, Sterling DA, Bleecker E, Donohue J. Changing patterns in asbestos-induced lung disease. Chest 2004; 125:744-753.
28. Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res 2006; 7:52.
29. Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006; 129:1305-1312.
30. Stratelis G, Molstad S, Jakobsson P, Zetterstrom O. 2006 ABS88: Diagnosis of COPD combined with brief smoking cessation advice increases smoking cessation rate in comparison with those with normal lung function. Prim Care Respir J 2006 May 20; [Epub ahead of print].